APVO — Aptevo Therapeutics Balance Sheet
0.000.00%
- $3.74m
- -$4.97m
- 14
- 40
- 16
- 12
Annual balance sheet for Aptevo Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 40 | 45 | 22.6 | 16.9 | 8.71 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2.37 | 3.66 | 2.5 | 0 | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 47.3 | 52.6 | 27.4 | 19.1 | 10.7 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5.54 | 3.96 | 6.76 | 5.78 | 4.93 |
Other Long Term Assets | |||||
Total Assets | 53.5 | 56.6 | 34.2 | 24.8 | 15.6 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 14.5 | 34.8 | 8.71 | 7.22 | 6.21 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 37 | 55.4 | 16.2 | 12.6 | 10.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 16.6 | 1.22 | 18 | 12.2 | 4.75 |
Total Liabilities & Shareholders' Equity | 53.5 | 56.6 | 34.2 | 24.8 | 15.6 |
Total Common Shares Outstanding |